Ipamorelin, bone and muscle: what the rat studies found

Published August 28, 2026 · Artemis Labs

Ipamorelin was tested in rats for effects on growing bone, bone mineral content, muscle tension and nitrogen balance between 1999 and 2009. The headline results are real: bone grew longer, bone mineral content rose, and muscle tension improved in animals given a steroid that normally weakens them. The qualifications are equally real and rarely repeated. When bone mineral content was corrected for the animals’ increased body weight, the effect disappeared, and volumetric bone density did not change — the bones were bigger, not denser. In a separate mouse study, the same class of compounds increased body fat through a route that did not involve growth hormone at all.

Key findings

• In adult female rats over 15 days, ipamorelin “dose-dependently increased LGR from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001)” — longitudinal growth rate at the tibia (PMID 10373343).
• The same study found the treatment “did not affect total IGF-I levels, IGFBPs, or serum markers of bone formation and resorption.”
• Over 12 weeks, bone mineral content rose — but “total BMC corrected for the increase in body weight (total BMC:body weight ratio) was unaffected” and “the cortical volumetric BMD was unchanged” (PMID 10828840).
• Against steroid-induced loss, combined treatment raised “the periosteal bone formation rate … four-fold” compared with steroid alone (PMID 11735244).

Bone length in growing rats

The 1999 study is the cleanest of the group. Adult female rats received one of three doses or vehicle, three times daily for fifteen days. Researchers marked the growing region of the tibia with tetracycline on days 0, 6 and 13 — the marker fluoresces and is laid down in the bone as it grows, so the distance between bands is a direct physical measure of growth rate.

Growth rate rose with dose, from 42 micrometres a day in controls to 52 in the highest group, and body weight gain rose too. What did not change is as interesting: total IGF-1, the binding proteins that carry it, and the blood markers of bone turnover all stayed where they were. Growth happened without the biochemical signature you would expect to accompany it.

The authors closed with a sentence that has aged well: “Whether ipamorelin or other GH secretagogues may have a place in the treatment of children with growth retardation requires demonstration in future clinical studies.” Twenty-seven years later, those studies have not been published.

Bone mineral content, and the correction that matters

The 2000 study ran longer — twelve weeks, in thirteen-week-old female rats — and compared ipamorelin, GHRP-6 and growth hormone itself against vehicle. Bone mineral content measured by DXA rose with all three treatments.

Then the authors did the thing that separates a careful study from a promotional one. They asked whether the extra mineral was simply because the animals were bigger. Corrected for body weight, the effect on total bone mineral content was gone. They went further, measuring the femurs directly by computed tomography and by Archimedes’ principle, and found the same thing from a different angle: the cross-sectional bone area had increased, while the volumetric density had not.

Their conclusion states it plainly: “the increases in cortical and total BMC were due to an increased growth of the bones with increased bone dimensions, whereas the volumetric BMD was unchanged.”

Bigger bones, not denser bones. The distinction is the whole finding, and any summary that says ipamorelin “increases bone density” reports the opposite of what this study measured.

Muscle and nitrogen balance under steroid treatment

Two studies tested ipamorelin against the catabolic effects of glucocorticoids — steroids that break down muscle and bone.

In the 2001 study, eight-month-old female rats received methylprednisolone, ipamorelin, or both, for three months. In the combination group, maximum tetanic tension in the calf muscles was significantly higher and the periosteal bone formation rate was four times that of the steroid-only group.

The 2009 study looked at nitrogen handling in the liver of prednisolone-treated rats. Ipamorelin reduced the liver’s urea-synthesis capacity by 20% and neutralized nitrogen balance. Growth hormone itself did better on the same measures — a 33% reduction, and nitrogen balance rose 2.5-fold in the same experiment — and the authors said so directly, noting the effects were achieved “though at the doses given less efficiently by the latter.”

An honest comparison against the reference treatment, published by the people running the experiment, is worth more than a favorable number without one.

What the research does not show

None of this is human research. Every study on this page is in rats, and the results describe rat physiology under specific experimental conditions.

Bone density did not increase. The bones grew larger, and the mineral content rose in proportion — correcting for body weight removed the effect, and direct density measurement found no change.

The body-composition picture includes a result that runs the other way. In mice, ipamorelin and GHRP-6 increased fat pad weight relative to body weight, and this happened even in growth-hormone-deficient animals. The authors concluded that these compounds “increase body fat by GH-independent mechanisms that may include increased feeding” (PMID 11162489). Appetite is part of what this receptor does.

And there is no published human study of ipamorelin and bone or muscle at all. The two human studies that exist measured pharmacokinetics and bowel recovery — see our page on the human trials.

Frequently asked questions

Did ipamorelin build bone in these studies?

It increased bone size and length in growing rats. It did not increase bone density, and the mineral-content gain did not survive correction for body weight.

Did IGF-1 rise?

Not in the 15-day study — total IGF-1 and its binding proteins were unchanged. In the steroid model, IGF-1 rose alongside repeated dosing.

What did these studies report about fat?

In the mouse study cited above, growth hormone secretagogues increased body fat, apparently through appetite rather than through growth hormone. Growth hormone itself reduced relative fat mass in the same experiment. They are not the same intervention.

How do these results relate to the selectivity finding?

They are a useful check on it. A compound can be selective about which pituitary hormones it moves and still have several effects on the animal. Our selectivity page covers what that study did and did not establish.

References

1. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Growth Horm IGF Res. 1999. PMID 10373343. DOI 10.1054/ghir.1999.9998.
2. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, et al. J Endocrinol. 2000. PMID 10828840. DOI 10.1677/joe.0.1650569.
3. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. Growth Horm IGF Res. 2001. PMID 11735244.
4. Aagaard NK, et al. Growth Horm IGF Res. 2009. PMID 19231263.
5. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Biochem Biophys Res Commun. 2001. PMID 11162489.

Methodology: every figure on this page is quoted from the published abstract of the study named beside it, retrieved through NCBI E-utilities on August 28, 2026. Species and study length are stated wherever a result is reported.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.